40 completed, 19 unknown, 5 terminated, 2 recruiting. 50 Phase 2, 16 Phase 3, 12 Phase 1.
Follow titanium silicide: new trials by email Literature Review of titanium silicide trials Research Report on titanium silicide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DURATION-GC: FLOT Plus Durvalumab and TS-1 Plus Durvalumab for Resectable Gastric Cancer Durvalumab, TS-1 - Resectable Gasrtic Cancer | Phase 2 | Not yet recruiting | Taipei Veterans General Hospital, Taiwan | 35 | 2026-09-01 | 2026-08-11 |
| Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, PD-1 inhibitor, TS-1 - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 84 | 2025-11-18 | 2026-01-06 |
| Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer D07001-softgel capsules + Xeloda (or TS-1), mFOLFOX - Biliary Tract Cancer | Phase 2 / Phase 3 | Recruiting | InnoPharmax Inc. | 180 | 2022-03-29 | 2025-04-30 |
| Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer leucovorin, oxaliplatin, docetaxel, S-1 - Gastric Cancer, Gastric Adenocarcinoma | Phase 2 | Unknown | National Cheng-Kung University Hospital | 58 | 2021-12-10 | 2023-11-15 |
| NGS as the First-line Treatment in Advanced Biliary Tract Cancer TS-1, Gemcitabine, Nivolumab - Advanced Biliary Tract Cancer | Phase 2 | Completed | National Health Research Institutes, Taiwan | 48 | 2019-12-27 | 2025-07-22 |
| Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659) Pembrolizumab, Oxaliplatin, TS-1 - Gastric Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 100 | 2018-03-26 | 2024-06-11 |
| S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Irinotecan - Pancreatic Ductal Adenocarcinoma | Phase 2 | Unknown | National Taiwan University Hospital | 35 | 2017-11-01 | 2017-10-20 |
| Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. TBI-1401(HF10), Gemcitabine, Nab-paclitaxel - Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV | Phase 1 | Active not recruiting | Takara Bio Inc. | 36 | 2017-09-25 | 2024-12-09 |
| Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer Docetaxel, S-1 - Advanced Gastric Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 47 | 2017-06-01 | 2017-05-08 |
| Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma TS-1 + cisplatin, radiation - Gastric Adenocarcinoma | Phase 2 | Completed | Yonsei University | 102 | 2016-12-12 | 2024-12-27 |
| Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes Gemcitabine, TS-1 with radiation - Pancreatic Neoplasms | Phase 2 | Unknown | Peking Union Medical College Hospital | 110 | 2016-03-01 | 2016-04-28 |
| S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy S-1 (452500ACH), OXALIPLATIN (205803BIJ) - Stomach Cancer | Phase 2 | Terminated | Kangbuk Samsung Hospital | 8 | 2015-05-01 | 2022-12-08 |
| Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer Oxaliplatin, Irinotecan, S-1(OIS) - Stomach Neoplasm | Phase 2 | Completed | Hallym University Medical Center | 44 | 2015-02-01 | 2017-08-23 |
| A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma SIB-IMRT, S-1, Surgery - Stomach Neoplasms, Neoadjuvant Therapy | Phase 2 | Completed | Chinese Academy of Medical Sciences | 71 | 2014-01-01 | 2019-10-16 |
| First Line Chemotherapy for Advanced Cancer albumin-bounded paclitaxel, S-1 - Gastric Cancer | Phase 2 | Terminated | Chinese Academy of Medical Sciences | 36 | 2013-09-01 | 2016-06-14 |
| Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial TS-1, oxaliplatin - Gastric Cancer | Phase 3 | Unknown | Samsung Medical Center | 547 | 2013-02-06 | 2020-03-25 |
| SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer SOX, XELOX - Colorectal Neoplasm | Phase 2 | Unknown | The First People's Hospital of Changzhou | 60 | 2013-01-01 | 2016-08-19 |
| Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer Gemcitabine, S-1 - Biliary Tract Cancer | Phase 2 | Completed | Kansai Hepatobiliary Oncology Group | 70 | 2013-01-01 | 2018-05-16 |
| S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer S-1, Cisplatin, Oxaliplatin - Gastric Cancer | Phase 3 | Completed | Min-Hee Ryu | 338 | 2012-12-01 | 2015-11-30 |
| Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer Docetaxel, Cisplatin, S-1 - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 40 | 2012-09-01 | 2012-12-12 |
Showing 20 of 70. Sign in to see all of them.
Stomach Neoplasms (31) · Pancreatic Neoplasms (8) · Colorectal Neoplasms (7) · Biliary Tract Neoplasms (5) · Neoplasm Metastasis (4) · Breast Neoplasms (3) · Carcinoma, Hepatocellular (2) · Gastrointestinal Neoplasms (2) · Recurrence (2) · Bile Duct Neoplasms (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1)
Hallym University Medical Center (7) · Chinese Academy of Medical Sciences (6) · Yonsei University (5) · Taiho Pharmaceutical Co., Ltd. (4) · Hokkaido Gastrointestinal Cancer Study Group (3) · Japan Clinical Cancer Research Organization (3) · Samsung Medical Center (3) · Chonnam National University Hospital (2) · Kansai Hepatobiliary Oncology Group (2) · National Cancer Center, Korea (2) · National Health Research Institutes, Taiwan (2) · Andrew Ko (1) · Asan Medical Center (1) · AstraZeneca (1) · Fujian Cancer Hospital (1)
South Korea (26) · Japan (21) · China (13) · Taiwan (6) · United States (2) · Argentina (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Croatia (1) · Estonia (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1)
Dae Young Zang, MD, PhD (6) · Hiroaki Nagano, MD, PhD (2) · Kenichi Sugihara, MD, PhD (2) · Lin Yang, MD (2) · Sang-Hee Cho, M.D.Ph.D. (2) · Aiping Zhou, M.D (1) · Andrew Ko, MD (1) · Atsushi Sofuni, M.D. PhD (1) · Binghe Xu, MD, PhD (1) · Chang Hak Sohn, M.D.PhD. (1) · Changping Wu, M.D. (1) · Chen Ming-Huang, MD (1) · Chia Jui Yen, M.D., Ph.D. (1) · Chiang Nai-Jung, MD (1) · Dae Young Zang, DM, PhD (1)
PMID 38140879, PMID 15160338, PMID 15169795, PMID 15289858, PMID 16803844, PMID 16822992, PMID 17978289, PMID 18282805, PMID 18553228, PMID 20708966, PMID 21444866, PMID 23497365, PMID 23547081, PMID 24366758, PMID 24942277, PMID 25106731, PMID 26109630, PMID 26216386, PMID 28210843, PMID 28911091, PMID 29372461, PMID 29678146, PMID 29743043, PMID 30425843, PMID 30982686, PMID 31765987, PMID 32145474, PMID 32596783, PMID 35574368, PMID 40885799